Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2025
vol. 76
 
Share:
Send email
Share:
Original paper

Clinicopathological and molecular features of non-small cell lung cancer that transform to small-cell lung cancer: Case reports and literature review

Qiqi Gao
1
,
Lixin Zhang
2
,
Yulong Zheng
3

  1. Department of Pathology, the First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China
  2. Department of Pathology, Xinchang Hospital of Traditional Chinese Medicine, Xinchang, China
  3. Department of Medicine-Oncology, the First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China
Pol J Pathol 2025; 76 (2): 94-109
DOI: https://doi.org/10.5114/pjp.2025.153971
Online publish date: 2025/09/22
Article files
- PJP-03071 Suppl. Table 1.pdf  [1.36 MB]
- PJP-03071.pdf  [3.61 MB]
Get citation
 
PlumX metrics:
 
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cispla­tin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lan­cet Oncol 2010; 11: 121-128.
4. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastat­ic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
5. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895- 2899.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carbopla­tin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
7. Farago AF, Piotrowska Z, Sequist LV. Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma. J Clin Oncol 2017; 35: 2987-2988.
8. Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transforma­tion from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-e172.
9. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
10. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377: 1919-1929.
11. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 1627-1639.
12. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379: 2040-2051.
13. Shen Q, Qu J, Sheng L, Gao Q, Zhou J. Case Report: Transfor­mation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases. Front Oncol 2021; 11: 619371.
14. Sehgal K, Varkaris A, Viray H, VanderLaan PA, Rangachari D, Costa DB. Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or un­der-recognized? J Immunother Cancer 2020; 8: e000697.
15. Ahn S, Hwang SH, Han J, et al. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. J Pathol Transl Med 2016; 50: 258-263.
16. Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. Oncol Lett 2018; 16: 4219-4222.
17. Ferrer L, Giaj Levra M, Brevet M, et al. A Brief Report of Transformation From NSCLC to SCLC: Molecular and Ther­apeutic Characteristics. J Thorac Oncol 2019; 14: 130-134.
18. Iams WT, Beckermann KE, Almodovar K, et al. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Re­port of Two Cases. J Thorac Oncol 2019; 14: e45-e48.
19. Bar J, Ofek E, Barshack I, et al. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer 2019; 138: 109-115.
20. Okeya K, Kawagishi Y, Muranaka E, et al. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcino­ma to Small-cell Carcinoma during Pembrolizumab Therapy. Intern Med 2019; 58: 3295-3298.
21. Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl) 2018; 9: 85-90.
22. Imakita T, Fujita K, Kanai O, et al. Small cell lung cancer transformation during immunotherapy with nivolumab: A case report. Respir Med Case Rep. 2017; 21: 52-55.
23. Takegawa N, Hayashi H, Iizuka N, Terashima T, Mio T. Trans­formation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol 2016; 27: 953-955.
24. Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. J Thorac Oncol 2016; 11: e67-e72.
25. Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcino­ma-Like Transformation and Resistance to Crizotinib. J Thorac Oncol 2016; 11: e55-e58.
26. Levacq D, D'Haene N, de Wind R, Remmekink M, Bergh­mans T. Histological transformation of ALK rearranged ade­nocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Lung Cancer 2016; 102: 38-41.
27. Zhu YC, Liao XH, Wang WX, et al. Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. Onco Targets Ther 2017; 10: 3187-3192.
28. Miyamoto S, Ikushima S, Ono R, et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol 2016; 46: 170-173.
29. Ren X, Cai X, Li J, et al. Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib. J Int Med Res 2020; 48: 300060520927918.
30. Zhou YZ, Jin J, Tian PW, Li WM. Application of the Next-Generation Sequencing Technology to Reveal Mecha­nism of Small Cell Lung Cancer Transformation from Adeno­carcinoma. Chin Med J (Engl) 2018; 131: 1124-1125.
31. Zhang Y, Li XY, Tang Y, et al. Rapid increase of serum neuron spe­cific enolase level and tachyphylaxis of EGFR-tyrosine kinase in­hibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer 2013; 81: 302-305.
32. Minari R, Bordi P, Del Re M, et al. Primary resistance to osime­rtinib due to SCLC transformation: Issue of T790M determina­tion on liquid re-biopsy. Lung Cancer 2018; 115: 21-27.
33. Ma S, He Z, Fu H, et al. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-gen­eration EGFR-TKIs: a case report. Transl Lung Cancer Res 2020; 9: 139-143.
34. Chu X, Li Y, Zhu Z. A Case of Small Cell Lung Cancer Trans­formation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib. J Thorac Oncol 2018; 13: e211-e214.
35. Liu J, Li X, Peng J. A Novel CAV1-MET Fusion in SCLC Transformation Responds to Crizotinib and Osimertinib Treat­ment. J Thorac Oncol 2019; 14: e126-e128.
36. Nishikawa S, Tambo Y, Ninomiya H, et al. A case treated with nivolumab after small cell lung cancer transformation of mu­tant EGFR non-small cell lung cancer. Ann Oncol 2016; 27: 2300-2302.
37. Lee JK, Lee J, Kim S, et al. Clonal History and Genetic Predic­tors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol 2017; 35: 3065-3074.
38. Lu H, Chen B, Qin J, Xie F, Han N, Huang Z. Transforma­tion to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. Oncol Lett 2018; 15: 5799-5802.
39. Fang L, He J, Xia J, et al. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transfor­mation from lung adenocarcinoma to small cell lung cancer: A case report. Oncol Lett 2017; 14: 593-598.
40. Fallet V, Ruppert AM, Poulot V, et al. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung can­cer transformation in the same patient. J Thorac Oncol 2012; 7: 1061-1063.
41. Suda K, Murakami I, Sakai K, et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep 2015; 5: 14447.
42. Liu Y. Small cell lung cancer transformation from EGFR-mu­tated lung adenocarcinoma: A case report and literatures re­view. Cancer Biol Ther 2018; 19: 445-449.
43. Jiang SY, Zhao J, Wang MZ, et al. Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcino­ma: A Case Report and Review of Literature. Medicine (Balti­more) 2016; 95: e2752.
44. Alì G, Bruno R, Giordano M, et al. Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocar­cinoma. Oncol Lett 2016; 12: 4009-4012.
45. Yang H, Liu L, Zhou C, et al. The clinicopathologic of pulmo­nary adenocarcinoma transformation to small cell lung cancer. Medicine (Baltimore) 2019; 98: e14893.
46. Shiroyama T, Nasu S, Tanaka A, et al. Transformation to small cell lung cancer after first-line afatinib treatment. Respir Med Case Rep 2018; 23: 188-190.
47. Hwang KE, Jung JW, Oh SJ, et al. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mu­tant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin. Tumori 2015; 101: e96-8.
48. Watanabe S, Sone T, Matsui T, et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine ki­nase inhibitors in a patient with lung adenocarcinoma. Lung Cancer 2013; 82: 370-372.
49. Ham JS, Kim S, Kim HK, et al. Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. J Thorac Oncol 2016; 11: e1-4.
50. 50. Gu Y, Zhu X, Cao B, et al. Transformation to small cell lung cancer and activation of KRAS during long-term erlotin­ib maintenance in a patient with non-small cell lung cancer: A case report. Oncol Lett 2019; 17: 5219-5223.
51. Xie T, Li Y, Ying J, et al. Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Transl Lung Cancer Res 2020; 9: 2428-2439.
52. Si X, You Y, Zhang X, Wang H, Wang M, Zang L. Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thorac Cancer 2020; 11: 793-796.
53. Miura N, Matsubara T, Takamori S, et al. Histological conver­sion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report. Oxf Med Case Reports 2020; 2020: omaa026.
54. Balla A, Khan F, Hampel KJ, Aisner DL, Sidiropoulos N. Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung. Cold Spring Harb Mol Case Stud 2018; 4: a002394.
55. Ou SI, Lee TK, Young L, et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 2017; 106: 110-114.
56. Xia G, Huang J, Ni J, et al. Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Transl Lung Cancer Res 2023; 12: 637-646.
57. Fang G, Liu W, Shang Y, et al. Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report. Ann Transl Med 2022; 10: 115.
58. Yu L, Bazhenova L, Gold K, et al. Clinicopathologic and mo­lecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res 2022; 11: 452-461.
59. Vendrell JA, Quantin X, Serre I, Solassol J. Combination of tissue and liquid biopsy molecular profiling to detect transfor­mation to small cell lung carcinoma during osimertinib treat­ment. Ther Adv Med Oncol 2020; 12: 1758835920974192.
60. Hui M, Uppin SG, Stalin BJ, Sadashivudu G. Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with re­view of literature. Lung India 2018; 35: 160-163.
61. Jin CB, Yang L. Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases. World J Clin Cases 2021; 9: 4617-4626.
62. Tokaca N, Wotherspoon A, Nicholson AG, Fotiadis N Thomp­son L, Popat S. Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer 2017; 111: 65-68.
63. Zhou Y, Bai H, Xia J, Xu WY, Cheng L, Xiong L. Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors. Ann Transl Med 2021; 9: 1150.
64. Pignataro D, Bertaglia V, Bironzo P, et al. Oligoprogres­sive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules. J Thorac Oncol 2020; 15: e170-e172.
65. Tang K, Jiang N, Kuang Y, et al. Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib. Thorac Cancer 2019; 10: 359-364.
66. Wang X, Liang J, Li L, Pan Z, Wang L. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarci­noma with de-novo epidermal growth factor receptor T790M mutation: case report. Anticancer Drugs 2023; 34: 306-310.
67. Wahab A, Kesari K, Chaudhary S, et al. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation? Cancer Biol Ther 2017; 18: 940-943.
68. Hong E, Chen XE, Mao J, et al. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report. World J Clin Cases 2022; 10: 2836-2843.
69. Zhang C, Lin L, Guo X, Chen P. Significance of genetic se­quencing in patients with lung adenocarcinoma with transfor­mation to small cell lung cancer: a case report and systematic review. Transl Cancer Res 2020; 9: 3725-3733.
70. Taniguchi Y, Horiuchi H, Morikawa T, Usui K. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma af­ter Osimertinib Treatment: A Case Report. Case Rep Oncol 2018; 11: 323-329.
71. Otoshi R, Sekine A, Okudela K, et al. Small-cell lung carci­noma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report. Mol Clin Oncol 2020; 13: 129-132.
72. El Hussein S, Khader SN. Transformation of lung adenocarcino­ma to small cell lung carcinoma in the setting of tyrosine kinase inhibitor therapy: Cytological approach of a clinically challeng­ing phenomenon. Diagn Cytopathol 2019; 47: 845-850.
73. Lai L, Meng W, Wei J, et al. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports. Medicine (Baltimore) 2021; 100: e25046.
74. Hao L, Chen H, Wang L, et al. Transformation or tumor heter­ogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcino­ma to small-cell lung cancer. Thorac Cancer 2023; 14: 1036- 1041.
75. Popat S, Wotherspoon A, Nutting CM, Gonzalez D, Nicholson AG, O'Brien M. Transformation to “high grade” neuroendo­crine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 80: 1-4.
76. Xie Z, Gu Y, Lin X, et al. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report. Cancer Biol Ther 2019; 20: 1172-1175.
77. Simarro J, Pérez-Simó G, Mancheño N, et al. Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with an EGFR Mutated Advanced Non-Small Cell Lung Cancer: A Case Report. Diagnostics (Ba­sel) 2022; 12: 1266.
78. Liu H, Chen LH, Zhang ZH, et al. Histomorphological trans­formation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. Front Oncol 2022; 12: 1022705.
79. Gazeu A, Aubert M, Pissaloux D, et al. Small-Cell Lung Can­cer Transformation as a Mechanism of Resistance to Pralsetin­ib in RET-Rearranged Lung Adenocarcinoma: A Case Report. Clin Lung Cancer 2023; 24: 72-75.
80. Zhai X, Liu J, Liang Z, et al. Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Muta­tion and High PD-L1 Expression After Immunotherapy Re­sistance, Which Finally Transform Into Small Cell Carcinoma. Front Oncol 2021; 11: 661034.
81. Leonetti A, Minari R, Mazzaschi G, Adrieansen D Song JY, Berns A. Small Cell Lung Cancer Transformation as a Resist­ance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Front Oncol 2021; 11: 642190.
82. Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol 2019; 37: 278-285.
83. Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Out­comes. J Thorac Oncol 2019; 14: 1784-1793.
84. Sutherland KD, Proost N, Brouns I, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in dis­tinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754-764.
85. Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A. 2014; 111: 4952-4957.
86. Mainardi S, Mijimolle N, Francoz S, Vicente-Dueñas C, Sánchez-García I, Barbacid M. Identification of cancer initiat­ing cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A 2014; 111: 255-260.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.